156 related articles for article (PubMed ID: 14675679)
21. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.
Francis P; Schneider J; Hann L; Balmaceda C; Barakat R; Phillips M; Hakes T
J Clin Oncol; 1994 Nov; 12(11):2301-8. PubMed ID: 7964944
[TBL] [Abstract][Full Text] [Related]
23. Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers.
Markman M; Webster K; Zanotti K; Kulp B; Peterson G; Belinson J
Gynecol Oncol; 2004 Oct; 95(1):109-13. PubMed ID: 15385118
[TBL] [Abstract][Full Text] [Related]
24. Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer.
Seliger G; Mueller LP; Kegel T; Kantelhardt EJ; Grothey A; Groe R; Strauss HG; Koelbl H; Thomssen C; Schmoll HJ
Int J Gynecol Cancer; 2009 Nov; 19(8):1446-53. PubMed ID: 20009905
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas.
Matsuo K; Eno ML; Im DD; Rosenshein NB
Arch Gynecol Obstet; 2010 Feb; 281(2):325-8. PubMed ID: 19455347
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Sabbatini P; Aghajanian C; Dizon D; Anderson S; Dupont J; Brown JV; Peters WA; Jacobs A; Mehdi A; Rivkin S; Eisenfeld AJ; Spriggs D
J Clin Oncol; 2004 Nov; 22(22):4523-31. PubMed ID: 15542803
[TBL] [Abstract][Full Text] [Related]
27. Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.
Markman M; Kennedy A; Sutton G; Hurteau J; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 1998 Aug; 70(2):272-4. PubMed ID: 9740704
[TBL] [Abstract][Full Text] [Related]
28. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study.
Coleman RL; Brady WE; McMeekin DS; Rose PG; Soper JT; Lentz SS; Hoffman JS; Shahin MS
Gynecol Oncol; 2011 Jul; 122(1):111-5. PubMed ID: 21497382
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel in the treatment of ovarian cancer.
Kavanagh JJ
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):73-81. PubMed ID: 12108900
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
[TBL] [Abstract][Full Text] [Related]
31. A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.
Monk BJ; Kauderer JT; Moxley KM; Bonebrake AJ; Dewdney SB; Secord AA; Ueland FR; Johnston CM; Aghajanian C
Gynecol Oncol; 2018 Dec; 151(3):422-427. PubMed ID: 30309721
[TBL] [Abstract][Full Text] [Related]
32. Docetaxel: an alternative taxane in ovarian cancer.
Katsumata N
Br J Cancer; 2003 Dec; 89 Suppl 3(Suppl 3):S9-S15. PubMed ID: 14661041
[TBL] [Abstract][Full Text] [Related]
33. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
Armstrong DK; White AJ; Weil SC; Phillips M; Coleman RL
Gynecol Oncol; 2013 Jun; 129(3):452-8. PubMed ID: 23474348
[TBL] [Abstract][Full Text] [Related]
34. Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
Cheng M; Lee HH; Chang WH; Lee NR; Huang HY; Chen YJ; Horng HC; Lee WL; Wang PH
Int J Environ Res Public Health; 2019 Nov; 16(23):. PubMed ID: 31795359
[TBL] [Abstract][Full Text] [Related]
35. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.
Markman M; Webster K; Zanotti K; Kulp B; Peterson G; Belinson J
Gynecol Oncol; 2003 Sep; 90(3):593-6. PubMed ID: 13678730
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.
Markman M; Hall J; Spitz D; Weiner S; Carson L; Van Le L; Baker M
J Clin Oncol; 2002 May; 20(9):2365-9. PubMed ID: 11981009
[TBL] [Abstract][Full Text] [Related]
37. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Matulonis UA; Sharma S; Ghamande S; Gordon MS; Del Prete SA; Ray-Coquard I; Kutarska E; Liu H; Fingert H; Zhou X; Danaee H; Schilder RJ
Gynecol Oncol; 2012 Oct; 127(1):63-9. PubMed ID: 22772063
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
Noguera IR; Sun CC; Broaddus RR; Branham D; Levenback CF; Ramirez PT; Sood AK; Coleman RL; Gershenson DM
Gynecol Oncol; 2012 Jun; 125(3):640-5. PubMed ID: 22387451
[TBL] [Abstract][Full Text] [Related]
40. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer.
Piccart MJ; Gore M; Ten Bokkel Huinink W; Van Oosterom A; Verweij J; Wanders J; Franklin H; Bayssas M; Kaye S
J Natl Cancer Inst; 1995 May; 87(9):676-81. PubMed ID: 7752272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]